thymalfasin has been researched along with Hepatitis--Chronic* in 4 studies
1 trial(s) available for thymalfasin and Hepatitis--Chronic
Article | Year |
---|---|
A pilot study of thymosin-alpha 1 therapy for chronic hepatitis D.
Topics: Adjuvants, Immunologic; Adult; Alanine Transaminase; Female; Follow-Up Studies; Hepatitis D; Hepatitis, Chronic; Humans; Male; Middle Aged; Pilot Projects; RNA, Viral; Thymalfasin; Thymosin | 1996 |
3 other study(ies) available for thymalfasin and Hepatitis--Chronic
Article | Year |
---|---|
Adding interventions to interferon in chronic HCV infections.
Topics: Chemotherapy, Adjuvant; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Thymalfasin; Thymosin | 1996 |
Combination thymosin alpha 1 and lymphoblastoid interferon treatment in chronic hepatitis C.
Monotherapy for chronic hepatitis C using interferon (IFN) results in a very small proportion of patients exhibiting a sustained response. Clinical trials assessing the benefit of combination drug therapy may provide evidence of improved treatment response over that seen with single drug treatment.. To assess the response in patients with chronic hepatitis C to one year of combination treatment: thymosin alpha 1 (T alpha 1), 1 mg twice weekly, and lymphoblastoid (L)-IFN, 3 MU thrice weekly.. Fifteen patients with serum HCV RNA positive chronic hepatitis C were studied. Eleven patients were treatment naive and four had failed previous standard IFN therapy. Thirteen patients were HCV RNA serotype 1b. All patients were given combination T alpha 1 and L-IFN therapy for one year with a six month follow up period.. Six months after initiation of treatment seven patients (47%) were sera HCV RNA negative and at completion of the one year treatment 11 (73%), including two who had failed previous standard IFN treatment, had negative serum HCV RNA. Six months after treatment, six patients (40%), including five with HCV type 1b, showed a sustained response characterized by a negative serum HCV RNA.. The results of this open label trial suggest that there may be a potential benefit to combining an immune modulator (T alpha 1) with an antiviral (IFN) in the treatment of chronic hepatitis C. Verification of the observations in this study require completion of a randomised controlled study. Topics: Adult; Aged; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Hepatitis, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Thymalfasin; Thymosin | 1996 |
[Characteristics of secondary immunologic deficiency in children with chronic hepatitis B and the methods of its correction].
A study was made of the immune system of patients with chronic HB-viral infection who showed the signs of secondary immundeficiency. The high frequency of the impairment of immunocompetent cells seen in chronic hepatitis B was established as was the appearance of different-temperature autolymphocytotoxins in response to the infection of mono-nuclears in all the disease stages. The treatment with thymalin proved effective in patients with the lack of cold autolymphocytotoxins or in those with low activity of the latter ones. The combined treatment (decaris plus prednisolone) turned out effective in children with a pronounced autoimmune component of the process (the presence of cold autolymphocytotoxins). It has been shown that the discovered interrelations between the different components of the immune system are conductive to the determination of the pathological process type and the choice of adequate therapy. Topics: Adjuvants, Immunologic; Child; Hepatitis B; Hepatitis, Chronic; Humans; Leukocyte Count; Lymphopenia; Rosette Formation; T-Lymphocytes; Thymalfasin; Thymosin | 1989 |